Discovery of Octahydroindenes as PAR1 Antagonists

ACS Med Chem Lett. 2013 Sep 10;4(11):1054-8. doi: 10.1021/ml400235c. eCollection 2013 Nov 14.

Abstract

Octahydroindene was identified as a novel scaffold for protease activated receptor 1 (PAR1) antagonists. Herein, the 2-position (C2) was explored for structure-activity relationship (SAR) studies. Compounds 14, 19, and 23b showed IC50 values of 1.3, 8.6, and 2.7 nM in a PAR1 radioligand binding assay, respectively, and their inhibitory activities on platelet activation were comparable to that of vorapaxar in a platelet rich plasma (PRP) aggregation assay. This series of compounds showed high potency and no significant cytotoxicity; however, the compounds were metabolically unstable in both human and rat liver microsomes. Current research efforts are focused on optimizing the compounds to improve metabolic stability and physicochemical properties as well as potency.

Keywords: Octahydroindene; PAR1 antagonist; PRP aggregation; antiplatelet; bleeding.